

Deliverable D6.3 (M48)

Report of use of social media, presentations in meetings and collaborations with other initiatives

Working Group 6 — Training and Dissemination

Leader: Rossitza Konakchieva

Co-Leader: Dinko Mitrecic

Science Communication Coordinator: Georgi Nikolaev

Document information	Details
Action title	Generation of human induced pluripotent stem cells from haplo-selected cord blood samples (HAPLO-iPS)
Action / deliverable	CA21151 / D6.3
Due month	M48
Action period	11 October 2022–10 October 2026
Evidence cut-off	6 October 2026; update for remaining Action days before submission
Status	Working draft — LinkedIn analytics incorporated; selected presentation details pending
Official website	https://haplo-ips.eu/
COST Action page	https://www.cost.eu/actions/CA21151/

1. Executive summary

Deliverable D6.3 reports the dissemination of HAPLO-iPS through social media, presentations at scientific and network meetings, and collaborations with related initiatives. It addresses WG6 tasks T6.3 and T6.4 and contributes to milestones M6.1 and M6.2. This report brings together the available Action records and public communication outputs, with an evidence cut-off of 6 October 2026.

The documented dissemination activities connect the Action's work on HLA-selected cord blood, hiPSC generation, quality control, biobanking, safety, ethics and clinical translation with relevant scientific communities. They include joint work with GAIT and NMDP, a joint stem cell standardisation meeting with ISCBI and ISCI in Hamburg, and conference contributions reported by the Working Groups. Young Researchers also presented their work and mobility experiences at dedicated network meetings.

The website provides a lasting record of announcements and activity reports, while LinkedIn promotes opportunities, reports events and amplifies members' contributions. The supplied analytics cover 5 October 2025–4 October 2026 and record 6,037 organic impressions, 340 clicks and 86 new organic followers. The overall interaction-to-impression rate calculated from the daily metrics is 8.81%. The Page had 315 followers on 6 October 2026, confirmed by the Science Communication Coordinator. These figures describe the available reporting year and current audience, not cumulative results for the full Action.

The strongest documented outcomes are the delivery of joint scientific events, dissemination of Action-related findings and the involvement of partner networks in scientific discussions and outputs. Evidence of clinical uptake, policy influence or durable collaboration beyond the Action cannot be established from the present materials alone. Annexes identify the information needed to complete and validate the final report.

2. Objectives, scope and evidence

2.1. Alignment with the Memorandum of Understanding

The MoU identifies dissemination through the website, social media, network meetings and international conferences as a WG6 objective. It also envisages contributions to other stem cell and ATMP initiatives, knowledge sharing with expert and young researcher communities, and dissemination of consensus documents and scientific achievements. D6.3 specifically concerns social media use, meeting presentations and collaborations.

MoU element	Contribution documented in D6.3
T6.3: Social media promotion	Official LinkedIn Page communication, dated daily metrics and audience profile; discontinuation of active X use.
T6.4: Presentations and collaborations	External conferences, joint meetings and engagement with GAIT/NMDP, ISCBI/ISCI, hPSCreg and EATRIS Bulgaria.
M6.1 / M6.2	Knowledge dissemination to experts and young scientists; visibility through digital channels, meetings and relevant initiatives.

3. Use of social media and digital communication

3.1. LinkedIn

HAPLO-iPS maintained an official LinkedIn Page at <https://www.linkedin.com/company/haplo-ips/>, administered by the Science Communication Coordinator through his personal LinkedIn account. Its communication promoted training and grant opportunities, reported scientific and Young Researcher activities, and disseminated surveys and publication opportunities. Examples from the post export illustrate these communication activities and their individual performance. [18]

The selected reporting period was stated as 5 October 2025–6 October 2026. Each export actually contains 365 daily records ending on 4 October 2026. Personal-profile analytics are outside the scope of these Page exports.

Annex A presents the daily results, audience snapshot and post-level metrics. The daily series records 6,037 impressions, 340 clicks, 182 reactions, 3 comments and 7 reposts, yielding 532 interactions and a calculated overall rate of 8.81% ($532 \div 6,037$). Sponsored impressions and sponsored follower additions were zero. The 86 new followers were organic additions; they cannot establish net growth without follower-loss and historical baseline data.

3.2. X/Twitter

The Action initially used Twitter, subsequently renamed X, at <https://twitter.com/HaploiPS/>. The Science Communication Coordinator reported that platform changes and access limitations led him to focus communication efforts on the official HAPLO-iPS LinkedIn Page. This represents a shift in the channel strategy rather than a continuing two-platform campaign. No comparable X analytics are available for the present assessment.

3.3. Relationship with the website

The website served as a source of structured information on the Action, Working Groups, calls and activities. Its public records document scientific meetings, the GAIT collaboration, Young Researchers activities and the dissemination of STSM experiences. Social media posts can direct readers to these longer reports and practical information. The present deliverable focuses on this dissemination role, with website establishment addressed separately in D6.2.

Communication purpose	Examples of documented content
Promoting participation	Training School registration; STSM and conference-grant opportunities.
Reporting scientific activities	GAiT workshop material; standardisation meeting; scientific conference reports.
Giving visibility to Young Researchers	Lisbon meeting report, STSM presentations and member contributions.
Supporting continuity	Announcements of future scientific events and publication opportunities.

3.4. Audience and interpretation of performance

The audience snapshot supports alignment with the Action's scientific community: Biotechnology Research accounts for 25.4% of followers, Higher Education 17.5% and Research Services 17.1% (approximately 60% combined). Research is the largest job-function category (27.6%), followed by Education (11.1%). Senior professionals represent 40.3%, Entry-level followers 24.1% and Training 4.1%. These platform categories describe the current audience; they do not identify COST Young Researcher status or measure clinical uptake. The post-level snapshot shows the Lisbon YR meeting report with 1,056 impressions and the ESGCT announcement with the highest engagement rate among the exported posts (21.21%).

4. Presentations in scientific and network meetings

4.1. External dissemination register

Table 1 compiles external contributions identified in the supplied WG reports and public Action records. Items requiring confirmation are labelled. Attendance and grant records alone do not establish the exact title or format of a presentation.

Date / venue	Event and contribution
June 2023 Venue not stated	WMDA Cord Blood Working Group: contact with cord blood banks and presentation reported by WG1.
14 July 2024 Hamburg, Germany	Joint ISCBI / ISCI / HAPLO-iPS meeting. Begoña Aran presented the Action; WG3, WG4 and WG5 leaders contributed.
7–9 November 2024 Sofia, Bulgaria	EATRIS Bulgaria conference “Advances in Translational Medicine”. Action representation included Anna Veiga, Leonardo Martin, Ying Chen and Anna Brymova.
6–8 March 2025 Frankfurt, Germany	IGLD/GSCN Annual Conference: Gerald Schumann, “Safety of pluripotent stem cell-derived ATMPs”, invited speaker.
7–8 June 2025 Beijing, China	PSConference2025: lectures by Glyn Stacey, Andreas Kurtz and Andras Dinnyes; session on analytical methods for stem cell applications.
24 June 2025 Aachen, Germany	Lecture-series contribution by Gerald Schumann on PSC-based cell and gene therapy, genome integrity and risk assessment.
7–10 October 2025 Seville, Spain	32nd ESGCT Annual Congress: Belén Alvarez Palomo presented a HAPLO-iPS poster including the clinical iPSC/ATMP questionnaire (WG7). The Page also reports contributions by Miquel de Homdedeu on macrophages derived from iPSC haplotypes.
1 December 2025 London, UK	HAPLO-iPS / GaIT workshop on iPSC–cord blood–derived haplobanks, Royal College of Pathologists.
April 2026 Edinburgh, UK	EFI meeting: “Optimizing iPSC Haplobanking for Europe: A Federated Approach to Enhance Patient HLA Coverage”, abstract 1381. Helen Latsoudis received an ITC grant.
3–5 June 2026 Mátraháza, Hungary	HUPHAR2026, “ATMP developments and regulations”, chaired by Andras Dinnyes. Talks: “Regulatory progress towards novel cell and gene therapy ATMPs” (co-authors include Dinnyes and Melinda Zana); “Best practice in Norway on dynamic consent and regulatory requirements for hiPSC banks”, Joel C. Glover.

4.2. Presentations and exchange within the Action

Network meetings provided a forum for communicating Working Group findings, reviewing implementation and sharing expertise. At the Sofia WG and MC meetings on 4–5 September 2023, the Science Communication Plan was presented. The Amsterdam meeting on 15–16 May 2024 included WG progress reports and a GAiT contribution by David Turner on European coverage for iPSC banks. These activities connected internal reporting with specialist scientific exchange.

The first Young Researchers meeting took place in Heraklion on 12 May 2025 ahead of the WG and MC sessions on 13–14 May. Its programme combined expert keynote lectures with short talks by Young Researchers, providing opportunities to discuss their work and develop contacts within the network.

At the second Young Researchers meeting in Lisbon on 18 May 2026, STSM participants presented experiences in clinical-trial data integration, iPSC workflows and cell cultivation and characterisation. The programme also included a keynote on hiPSC bioprocesses and a Young Researcher's reflection on the role of Action participation in her scientific development. These presentations illustrate the exchange of knowledge gained through mobility activities.

The Lisbon YR meeting was followed by WG and MC sessions on 19–20 May 2026. WG3 specifically reports presentations by Young Researchers at both Heraklion and Lisbon, including dissemination associated with STSMs by Meiyang Xue and Benjamin Kurtze. Training-related exchange also included WG2's first school on hiPSC reprogramming and characterisation and WG5's Oslo school on data management and protection, 18–19 September 2026; training delivery is reported separately in D6.1.

Meeting	Role in dissemination
Sofia, 4–5 September 2023	Science Communication Plan and WG progress reporting.
Amsterdam, 15–16 May 2024	WG scientific exchange and GAiT presentation on iPSC bank coverage.
Heraklion, 12–14 May 2025	First YR meeting, expert lectures, YR short talks and WG updates.
Lisbon, 18–20 May 2026	YR presentations and STSM exchange (18 May); WG and MC sessions (19–20 May).
Online, 15 September 2026	WG closure reporting and coordination of the D6.3 evidence collection.

5. Collaborations with other initiatives

5.1. GAIT, NMDP and cord blood banking networks

Collaboration between WG1 and GAIT/NMDP addressed the ranking of HLA haplotypes, population coverage and the design of a European iPSC haplobank. The Action website records discussions on adapting existing ranking and clustering tools, involvement of cord blood banks, and a prospective joint publication. These records describe a scientific collaboration with a defined methodological purpose, rather than general networking alone.

The joint HAPLO-iPS–GAIT workshop in London on 1 December 2025 brought together expertise in clinical translation, HLA and immunogenetics, starting materials, national haplobank initiatives and regulatory implementation. The supplied post-event account documents discussion of approaches from Spain, Germany, Greece and France and engagement with EU and UK regulatory perspectives. The workshop provided a forum for comparing donor-to-iPSC pathways and requirements for clinical-grade haplobanking.

WG1's September report links this collaboration to the EFI abstract on a federated European haplobank approach and to two manuscripts. "Building Clinical-Grade iPSC Haplobanks: A Donor-Centred Perspective" was reported as submitted in August 2026; the paper on optimising European HLA coverage was reported as in preparation. These are recorded with their reported status, without claiming acceptance or publication. Contact with WMDA's Cord Blood Working Group and invitations to affiliated banks also extended the exchange to the source-material community.

5.2. ISCBI, ISCI and hPSCreg

The Hamburg joint meeting connected HAPLO-iPS WG3, WG4 and WG5 with international stem cell biobanking and standardisation initiatives. Its programme linked scientific quality, genetic stability, regulatory pathways and resources for clinical use. The public account reports approximately 60 on-site participants and 25 virtual participants.

WG3's reported alignment with ISCBI, ISCI and hPSCreg through the joint workshop and online sub-workshops on quality control, consent, cost and cross-border resource sharing. Their final report also describes hPSCreg as a shared reference for cell-line registration and metadata. Sharing routes and resource-specific access policies still require formalisation.

5.3. EATRIS Bulgaria and INFRAACT

The Sofia conference in November 2024 offered a dissemination route to the translational medicine community through EATRIS Bulgaria and INFRAACT. HAPLO-iPS representatives contributed alongside researchers addressing cell technologies, biobanking, ethics and translational research. This is documented as conference-based engagement; the available evidence does not establish a formal institutional partnership agreement.

5.4. Collaborative publishing and editorial initiatives involving Action members

HAPLO-iPS members Helen Latsoudis and Belen Alvarez-Palomo participated as Topic Editors, alongside Julia Skokowa, in the Frontiers in Immunology Research Topic "The Significance of Induced Pluripotent Stem Cells in Translational Medicine". They also co-authored its editorial, published on 26 August 2026. The collection addresses themes relevant to the Action, including HLA-homozygous iPSC resources and clinical translation.

Additional Action members contributed scientific papers to this collection. Their involvement provided an opportunity to share research with the wider iPSC and translational medicine community through a common publishing initiative. This activity is recorded as editorial and author participation by Action members; the collection is not attributed to COST sponsorship or formal HAPLO-iPS coordination.

5.5. Outreach through related networks and follow-on collaboration

WG7 reports circulation of its clinical iPSC/ATMP questionnaire through TERA+ (the Spanish Network for Advanced Therapies), COST Actions BTCs4ATMP and COR-EU-STEM, and the French Society of Hematology. Alongside the ESGCT poster, this is a documented dissemination activity through related initiatives. WG7 notes that responses were few and further outreach was needed; no response total is supplied.

WG7 also reports a successful HORIZON HEALTH–TOOL1 proposal with five of twelve partners drawn from HAPLO-iPS: BST and CSIC (Spain), EATRIS (the Netherlands), PEI and Catalent (Germany). This is recorded as a reported follow-on collaboration opportunity.

6. Assessment of outcomes and continuity

6.1. Documented outputs and their relevance

Output	Relevance to the dissemination objective
Joint workshops and network presentations	Enabled exchange on haplobank design, standards, donor pathways and regulation.
External conference contributions	Brought Action-related work to immunogenetics, translational medicine and stem cell communities.
Young Researcher presentations	Shared mobility experience and research with peers and expert members.
Website and LinkedIn outputs	Publicised activities, opportunities and scientific developments.
Collaborative scientific outputs	WG1 abstract/manuscripts; member editorial and paper contributions; survey outreach through related networks and a reported follow-on proposal.

Together, these activities demonstrate implementation of several dissemination routes envisaged in the MoU. Their significance lies in linking complementary communities involved in clinically relevant hiPSC development. The available evidence supports a description of activities and scientific exchange.

6.2. Limitations

The current evidence is weighted towards recent WG reporting and public events. Quantitative LinkedIn analysis is limited to the 365 daily records available, and there is no equivalent X dataset. Daily unique-impression and visitor counts are not summed and described as unique people across the year. The post-level and daily exports contain different totals, especially for reposts, so they are retained as separate datasets rather than merged.

7. Conclusion

HAPLO-iPS used scientific meetings, joint workshops and digital communication to disseminate activities and exchange knowledge relevant to hiPSC haplobanking and clinical translation. The records demonstrate engagement with GAIT/NMDP and international standardisation initiatives, external scientific contributions, involvement in collaborative publishing initiatives and opportunities for Young Researchers to present their work. The available LinkedIn year shows organic visibility and interaction with an audience concentrated in research and education.

Annex A. LinkedIn analytics and audience

Official HAPLO-iPS Page; exports supplied on 6 October 2026. Selected interval: 5 October 2025–6 October 2026.

Metric	Result
Followers at snapshot	315
New followers in daily series	86
Impressions	6,037
Clicks	340
Reactions / comments / reposts	182 / 3 / 7
Interactions	532
Calculated overall engagement rate	8.81%
Click-through rate (calculated)	5.63%
Page views	224

Audience snapshot

Dimension	Leading categories	Interpretation
Industry	Biotechnology Research: 80 (25.4%) Higher Education: 55 (17.5%) Research Services: 54 (17.1%)	These three categories account for approximately 60% of the 315-follower snapshot.
Job function	Research: 87 (27.6%) Education: 35 (11.1%) Business Development: 26 (8.3%)	The audience includes scientific, education and innovation-related roles.
Seniority	Senior: 127 (40.3%) Entry: 76 (24.1%) Director: 27 (8.6%) Training: 13 (4.1%)	LinkedIn seniority labels do not identify age, career stage under COST definitions or YR status.

Examples of LinkedIn dissemination

The examples below reproduce individual-post metrics from the content export. They are not added to the daily-series results. Post topics link to their original LinkedIn updates. “Interactions” is calculated from the displayed clicks, likes, comments and reposts; engagement rates are the export’s post-level values.

Post date	Topic	Impressions	Clicks	Interactions	Engagement
21/09/2026	Oslo GDPR Training School report	483	40	68	14.08%
21/09/2026	YR-led journal collection	848	25	46	5.42%
03/07/2026	Oslo Training School registration	257	9	23	8.95%
18/06/2026	Paris symposium announcement	464	21	41	8.84%
28/05/2026	Lisbon Young Researchers meeting	1056	47	86	8.14%
05/02/2026	iPSC-derived ATMP survey reminder	53	0	5	9.43%
04/12/2025	Conference-grant call	233	10	16	6.87%
04/12/2025	STSM grant call	461	32	52	11.28%
24/10/2025	Tuğba Topal STSM report	524	18	34	6.49%
22/10/2025	iPSC-derived ATMP survey launch	780	37	66	8.46%
22/10/2025	ESGCT 2025 participation	547	89	116	21.21%

Comparison of the exports

The daily Metrics sheet totals 6,037 impressions and 7 reposts, whereas the All posts sheet totals 5,706 impressions and 46 reposts. The exports distinguish dates of views from dates of post creation, but do not fully explain the numerical differences. Accordingly, daily metrics are used for the period summary and individual-post rows are shown as supplied. The post-level figures are not described as a reconciled annual total.

The Lisbon Young Researchers meeting report has the highest impression count among the exported posts (1,056). The ESGCT 2025 participation post has the highest exported engagement rate (21.21%), with 547 impressions and 116 calculated interactions. These are descriptive comparisons within the exported list, without an external performance benchmark.